Ritu Baral
Stock Analyst at TD Cowen
(0.54)
# 3,022
Out of 4,413 analysts
24
Total ratings
26.09%
Success rate
-27.25%
Average return
Main Sectors:
Top Industries:
18 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SAGE Sage Therapeutics | Maintains: Buy | $30 → $16 | $13.28 | +20.48% | 4 | Apr 18, 2024 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Outperform | $349 → $390 | $210.59 | +85.19% | 1 | Mar 15, 2024 | |
| SGMT Sagimet Biosciences | Initiates: Outperform | n/a | $4.11 | - | 1 | Aug 8, 2023 | |
| SRPT Sarepta Therapeutics | Maintains: Outperform | $125 → $175 | $130.90 | +33.69% | 1 | Mar 22, 2023 | |
| INSM Insmed | Maintains: Outperform | $56 → $53 | $25.59 | +107.11% | 1 | Oct 21, 2022 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Outperform | $32 → $21 | $17.05 | +23.17% | 1 | Aug 8, 2022 | |
| SPRO Spero Therapeutics | Downgrades: Market Perform | n/a | $1.55 | - | 2 | May 4, 2022 | |
| ANTX AN2 Therapeutics | Initiates: Outperform | n/a | $2.40 | - | 1 | Apr 19, 2022 | |
| SPRB Spruce Biosciences | Downgrades: Market Perform | n/a | $0.72 | - | 1 | Nov 23, 2021 | |
| RLYB Rallybio | Initiates: Outperform | n/a | $1.90 | - | 1 | Aug 23, 2021 | |
| GHRS GH Research | Initiates: Outperform | n/a | $11.95 | - | 1 | Jul 20, 2021 | |
| ATAI Atai Life Sciences | Initiates: Outperform | n/a | $2.05 | - | 2 | Jul 13, 2021 | |
| VERA Vera Therapeutics | Initiates: Outperform | n/a | $42.32 | - | 1 | Jun 8, 2021 | |
| TERN Terns Pharmaceuticals | Initiates: Outperform | n/a | $5.08 | - | 1 | Mar 2, 2021 | |
| PLRX Pliant Therapeutics | Initiates: Outperform | n/a | $12.66 | - | 1 | Jun 29, 2020 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | n/a | $149.96 | - | 1 | Aug 13, 2018 | |
| ASNS Actelis Networks | Downgrades: Market Perform | n/a | $0.79 | - | 2 | Jul 2, 2018 | |
| AXON Axon Enterprise | Downgrades: Market Perform | n/a | $311.57 | - | 1 | Jan 12, 2018 |
Sage Therapeutics
Apr 18, 2024
Maintains: Buy
Price Target: $30 → $16
Current: $13.28
Upside: +20.48%
Madrigal Pharmaceuticals
Mar 15, 2024
Maintains: Outperform
Price Target: $349 → $390
Current: $210.59
Upside: +85.19%
Sagimet Biosciences
Aug 8, 2023
Initiates: Outperform
Price Target: n/a
Current: $4.11
Upside: -
Sarepta Therapeutics
Mar 22, 2023
Maintains: Outperform
Price Target: $125 → $175
Current: $130.90
Upside: +33.69%
Insmed
Oct 21, 2022
Maintains: Outperform
Price Target: $56 → $53
Current: $25.59
Upside: +107.11%
ACADIA Pharmaceuticals
Aug 8, 2022
Maintains: Outperform
Price Target: $32 → $21
Current: $17.05
Upside: +23.17%
Spero Therapeutics
May 4, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $1.55
Upside: -
AN2 Therapeutics
Apr 19, 2022
Initiates: Outperform
Price Target: n/a
Current: $2.40
Upside: -
Spruce Biosciences
Nov 23, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $0.72
Upside: -
Rallybio
Aug 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $1.90
Upside: -
GH Research
Jul 20, 2021
Initiates: Outperform
Price Target: n/a
Current: $11.95
Upside: -
Atai Life Sciences
Jul 13, 2021
Initiates: Outperform
Price Target: n/a
Current: $2.05
Upside: -
Vera Therapeutics
Jun 8, 2021
Initiates: Outperform
Price Target: n/a
Current: $42.32
Upside: -
Terns Pharmaceuticals
Mar 2, 2021
Initiates: Outperform
Price Target: n/a
Current: $5.08
Upside: -
Pliant Therapeutics
Jun 29, 2020
Initiates: Outperform
Price Target: n/a
Current: $12.66
Upside: -
Alnylam Pharmaceuticals
Aug 13, 2018
Maintains: Outperform
Price Target: n/a
Current: $149.96
Upside: -
Actelis Networks
Jul 2, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $0.79
Upside: -
Axon Enterprise
Jan 12, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $311.57
Upside: -